Nautilus Biotechnology Stock Investor Sentiment

NAUT Stock  USD 1.12  0.01  0.90%   
Slightly above 58% of Nautilus Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding Nautilus Biotechnology suggests that many traders are alarmed. Nautilus Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Nautilus Biotechnology's earnings reports, geopolitical events, and overall market trends.
  

Nautilus Biotechnology Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Nautilus Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at finance.yahoo.com         
This Nautilus Biotechnology Insider Increased Their Holding In The Last Year
Yahoo News
over a year ago at thelincolnianonline.com         
Acquisition by Sujal Patel of 2430 shares of Nautilus Biotechnology at 2.9885 subject to Rule 16b-3
news
over a year ago at thelincolnianonline.com         
Nautilus Biotechnology, Inc. CEO Sujal M. Patel Buys 18,854 Shares of Stock
news
over a year ago at www.macroaxis.com         
Acquisition by Sujal Patel of 18854 shares of Nautilus Biotechnology at 2.8866 subject to Rule 16b-3
Macroaxis News
over a year ago at www.macroaxis.com         
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
Macroaxis News
over a year ago at investing.com         
Acquisition by Sujal Patel of 7405 shares of Nautilus Biotechnology at 2.6464 subject to Rule 16b-3
Investing News at Macroaxis
over a year ago at investing.com         
Earnings call Nautilus Biotechnology delays new platform launch to 2025
Investing News at Macroaxis
over a year ago at thelincolnianonline.com         
Nautilus Biotechnology Posts Quarterly Earnings Results, Beats Estimates By 0.02 EPS
news
over a year ago at www.macroaxis.com         
Acquisition by Mary Godwin of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3
Macroaxis News
over a year ago at insidermonkey.com         
Nautilus Biotechnology, Inc. Q4 2023 Earnings Call Transcript
insidermonkey News
over a year ago at seekingalpha.com         
Nautilus Biotechnology files 300M mixed securities shelf
seekingalpha News
over a year ago at investing.com         
Nautilus Biotechnology earnings beat by 0.02, revenue was in line with estimates
Investing News at Macroaxis
over a year ago at investing.com         
Earnings call SkyWater Technology sees record Q4 revenue, eyes future growth
Investing News at Macroaxis
over a year ago at seekingalpha.com         
Nautilus Biotechnology GAAP EPS of -0.14 beats by 0.01
seekingalpha News
over a year ago at gurufocus.com         
Nautilus Biotechnology Inc Reports Fiscal Year 2023 Financial Results
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Nautilus Biotechnology that are available to investors today. That information is available publicly through Nautilus media outlets and privately through word of mouth or via Nautilus internal channels. However, regardless of the origin, that massive amount of Nautilus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nautilus Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nautilus Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nautilus Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nautilus Biotechnology alpha.

Nautilus Biotechnology Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Nautilus Biotechnology Trading Down 5.9 percent - Heres Why - MarketBeat
02/12/2025
2
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results
02/27/2025
3
Nautilus Biotechnology Inc Q4 2024 Earnings Call Highlights Progress in Proteome ...
02/28/2025
4
Acquisition by Subra Sankar of 160000 shares of Nautilus Biotechnology at 1.24 subject to Rule 16b-3
03/03/2025
5
Acquisition by Nelson Nicholas A. of 160000 shares of Nautilus Biotechnology at 1.24 subject to Rule 16b-3
03/07/2025
6
Acquisition by Nazem Farzad of 45000 shares of Nautilus Biotechnology at 2.56 subject to Rule 16b-3
03/14/2025

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.